Using population estimates by the U.S. Census and rate of diabetes statistics from the Center for Disease Control (CDC), we’ve estimated the number of insulin users in each state and congressional district in the U.S.

While they blame PBMs for the high price of insulin, insulin makers pocket 47% of the price, an 8 times increase from the 1990s.

The cost of insulin in the U.S. is almost 7 times more expensive than the next country.

Since 1996, insulin manufacturers have increased the price of a vial of insulin in the United States by almost 1200%.

The United States accounts for just 6% of the world’s diabetics, but 39.3% of the healthcare costs.

U.S. House of Representatives Committee on Oversight and Reform investigated pharma abuses of the healthcare system to increase profits at the expense of patients.

Most diabetes focused nonprofits receive donations from insulin makers. Understanding where these organizations get their funding can help find potential conflicts of interest.

Tracking political contributions from insulin manufacturers can expose politicians' potential bias towards the pharmaceutical industry.

Drug transparency laws have the potential to shed light on the closed door dealings of the healthcare system, increasing price regulation and accountability measures.

Co-pay caps are the most recent debate amongst diabetes advocates around the United States: Are they helpful or hurtful to the insulin access movement?